Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

被引:80
作者
Katzmann, J. A. [1 ]
Clark, R. [1 ]
Kyle, R. A. [2 ]
Larson, D. R. [3 ]
Therneau, T. M. [3 ]
Melton, L. J., III [4 ]
Benson, J. T. [3 ]
Colby, C. L. [3 ]
Dispenzieri, A. [2 ]
Landgren, O. [5 ]
Kumar, S. [2 ]
Bradwell, A. R. [6 ]
Cerhan, J. R. [4 ]
Rajkumar, S. V. [2 ]
机构
[1] Mayo Clin, Dept Lab Med, Div Clin Biochem & Immunol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA
[5] NCI, Multiple Myeloma Sect, Bethesda, MD 20892 USA
[6] Binding Site, Birmingham, W Midlands, England
基金
美国国家卫生研究院;
关键词
MGUS; multiple myeloma; prognosis; suppression; heavy/light; UNDETERMINED SIGNIFICANCE MGUS; PRECEDES MULTIPLE-MYELOMA; MONOCLONAL GAMMOPATHY; DIAGNOSIS; CRITERIA;
D O I
10.1038/leu.2012.189
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgG lambda in IgG kappa MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P = 0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology. Leukemia (2013) 27, 208-212; doi: 10.1038/leu.2012.189
引用
收藏
页码:208 / 212
页数:5
相关论文
共 17 条
[1]   Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications [J].
Bianchi, Giada ;
Kyle, Robert A. ;
Colby, Colin L. ;
Larson, Dirk R. ;
Kumar, Shaji ;
Katzmann, Jerry A. ;
Dispenzieri, Angela ;
Therneau, Terry M. ;
Cerhan, James R. ;
Melton, L. Joseph, III ;
Rajkumar, S. Vincent .
BLOOD, 2010, 116 (12) :2019-2025
[2]   Assessment of Monoclonal Gammopathies by Nephelometric Measurement of Individual Immunoglobulin κ/λ Ratios [J].
Bradwell, Arthur R. ;
Harding, Stephen J. ;
Fourrier, Nicolas J. ;
Wallis, Gregg L. F. ;
Drayson, Mark T. ;
Carr-Smith, Hugh D. ;
Mead, Graham P. .
CLINICAL CHEMISTRY, 2009, 55 (09) :1646-1655
[3]   Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma [J].
Cesana, C ;
Klersy, C ;
Barbarano, L ;
Nosari, AM ;
Crugnola, M ;
Pungolino, E ;
Gargantini, L ;
Granata, S ;
Valentini, M ;
Morra, E .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1625-1634
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[6]  
2-F
[7]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[8]   Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management [J].
Kyle, R. A. ;
Durie, B. G. M. ;
Rajkumar, S. V. ;
Landgren, O. ;
Blade, J. ;
Merlini, G. ;
Kroeger, N. ;
Einsele, H. ;
Vesole, D. H. ;
Dimopoulos, M. ;
San Miguel, J. ;
Avet-Loiseau, H. ;
Hajek, R. ;
Chen, W. M. ;
Anderson, K. C. ;
Ludwig, H. ;
Sonneveld, P. ;
Pavlovsky, S. ;
Palumbo, A. ;
Richardson, P. G. ;
Barlogie, B. ;
Greipp, P. ;
Vescio, R. ;
Turesson, I. ;
Westin, J. ;
Boccadoro, M. .
LEUKEMIA, 2010, 24 (06) :1121-1127
[9]   Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J].
Kyle, R. A. ;
Rajkumar, S. V. .
LEUKEMIA, 2009, 23 (01) :3-9